BIO 2003 Exhibitor Profiles.

Business Editors/Health/Medical Writers/High-Tech Writers

BIOWIRE2K

BIO 2003 Annual Convention

WASHINGTON--(BUSINESS WIRE)--June 20, 2003

The Biotechnology Industry Organization 2003 Annual Convention takes place June 22 - 25 at the Washington Convention Center

Listed below are profiles from BIO 2003 exhibitors. News releases and advisories are available at http://www.tradeshownews.com.

Company: BIOCOM
Booth: 1529
Media Contact: Jennifer Landress
Phone: 858-455-0300
E-mail: jlandress@biocom.org
Company URL: www.biocom.org

To position the Greater San Diego life science community to
achieve individual and collective success on the world stage of
scientific and technological innovation, and in the development of
products that improve global health and quality of life.

To be recognized by each of our members as the most valued
organization in strengthening and enhancing their potential for
success.

Company: Dyax Corp.
Ticker Symbol: DYAX
Booth: 317
Media Contact: Sondra Henrichon
Phone: 617-201-8377 (cell)
E-mail: ir@dyax.com
Company URL: www.dyax.com

Product description: Dyax has 2 recombinant small proteins, DX-88
and DX-890 compounds in advanced clinical development. DX-88 is in
Phase II clinical trials for a rare inflammatory condition called
hereditary angioedema, in collaboration with Genzyme Corp. DX-88 is
also in a Phase I/II trial for the prevention of blood loss and
effects of systemic inflammatory response syndrome in patients
undergoing coronary artery bypass graft surgery. DX-890 is in Phase
IIa studies for cystic fibrosis, in collaboration with DebioPharm
S.A.

Company description: Dyax is a fully integrated biopharmaceutical
company with 2 recombinant small proteins, DX-88 and DX-890, in Phase
II clinical development. Both compounds were identified utilizing
Dyax's proprietary phage display technology, which generates and
screens a massive number of antibodies, peptides and/or small proteins
against any particular disease target. Dyax currently generates
revenues from technology collaborations (licensees, funded research)
and sales from its wholly-owned separations subsidiary, Biotage, Inc.

Company:  Fraunhofer USA, Inc. Center for Molecular Biotechnology
Booth:  826 Delaware Pavilion
Media Contact: Yvonne Wessel
Phone: 302-369-8292
E-mail: ywessel@fraunhofer-cmb.org
Company URL: www.fraunhofer-cmb.org

Product description: Contract Research Services for Protein
Expression and Vaccines.

Company description: The Fraunhofer USA Center for Molecular
Biotechnology (FhCMB) is a not-for-profit, contract research
organization, developing and applying plant science and allied
technologies for the production of valuable proteins through molecular
farming. We have special expertise and proprietary know-how in a
platform technology known as transient gene expression, which rapidly
provides large amounts of product. We have a state-of-the-art research
facility located in the Delaware Technology Park, adjacent to the
University of Delaware main campus in Newark, DE, in which we produce
experimental vaccines, peptide hormones, enzymes and monoclonal
antibodies. Our experienced staff is our greatest asset. Meet them at
www.fraunhofer-cmb.org.

Company: Ligand Pharmaceuticals Inc.
Ticker Symbol: LGND
Booth: 1523
Media Contact: Therese Ghio
Investor Relations Contact: Michael Watts
Phone: 858/550-7500
E-mail: mwatts@ligand.com
Company URL: www.ligand.com

Product description: Targretin(R) (bexarotene) gel and
Targretin(R) capsules, approved for cutaneous T-cell lymphoma (CTCL);
Panretin(R) (alitretinoin) gel, for Kaposi's sarcoma; ONTAK(R)
(denileukin diftitox), for (CTCL); AVINZA(R) (morphine sulfate
extended-release capsules) for chonic moderate-to-severe pain.

Company description: Ligand Pharmaceuticals discovers, develops
and markets new drugs that address critical unmet medical needs of
patients in the areas of cancer, pain, skin diseases, men's and
women's hormone-related diseases, osteoporosis, metabolic disorders,
and cardiovascular and inflammatory diseases.